Published Online
on May 21, 2007

A more recent version of this article appeared on July 1, 2007

This Article Full Text (PDF) All Versions of this Article: 50/1/137    most recent HYPERTENSIONAHA.107.087700v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rana, S. Articles by Thadhani, R. Search for Related Content PubMed PubMed Citation Articles by Rana, S. Articles by Thadhani, R. Related Collections Other hypertension Related Article

Submitted on January 18, 2007
Revised on February 5, 2007

Sequential Changes in Antiangiogenic Factors in Early Pregnancy and Risk of Developing Preeclampsia

Sarosh Rana; S. Ananth Karumanchi; Richard J. Levine; Shivalingappa Venkatesha; Jose Alejandro Rauh-Hain; Hector Tamez; and Ravi Thadhani^*

From the Maternal Fetal Medicine Division (S.R.), Women and Infants Hospital, Brown University, Providence, RI; the Departments of Medicine, Obstetrics, and Gynecology (S.A.K., S.V.), Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass; the Division of Epidemiology, Statistics and Prevention Research (R.J.L.), National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, Md; and the Department of Medicine (J.A.R.-H., H.T., R.T.), Massachusetts General Hospital and Harvard Medical School, Boston, Mass.

^* To whom correspondence should be addressed. E-mail: rthadhani{at}partners.org.

Abstract--Concentrations of soluble fms-like tyrosine kinase 1 (sFlt1) and soluble endoglin (sEng) increase in maternal blood with the approach of clinical preeclampsia. Although alterations in these circulating antiangiogenic factors herald the signs and symptoms of preeclampsia, in vitro studies suggest they may also play a role in regulating early placental cytotrophoblast functions. Early pregnancy changes in sFlt1 and sEng may thus identify women destined to develop preeclampsia. We performed a nested case-control study of 39 women who developed preeclampsia and 147 contemporaneous normotensive controls each with serum collected in the first (11 to 13 weeks of gestation) and second (17 to 20 weeks) trimesters. Whereas levels of sFlt1 and sEng at 11 to 13 weeks were similar between cases and controls (sFlt1: 3.5±0.3 ng/mL versus 3.0±0.1, P=0.14; sEng 6.9±0.3 ng/mL versus 6.6±0.2, P=0.37, respectively), at 17 to 20 weeks both were elevated in the women destined to develop preeclampsia (sFlt1: 4.1±0.5 ng/mL versus 3.1±0.1, P<0.05; sEng, 6.4±0.4 ng/mL versus 5.2±0.1, P<0.01). Women who developed preterm (<37 weeks) preeclampsia demonstrated even greater sequential changes: difference [delta{d}] between second and first trimester levels: dsFlt1, 0.63±0.91 ng/mL in preterm PE versus 0.05±0.15 in controls; dsEng, 0.73±0.77 ng/mL versus -1.32±0.18, P<0.01. Similar findings were noted in a cross-sectional analysis of specimens collected from the Calcium for Preeclampsia Prevention Study. In conclusion, sequential changes in antiangiogenic factors during early pregnancy may be useful for predicting preterm preeclampsia.

Key words: antiangiogenic factors • sFlt1 • soluble endoglin • preeclampsia • predictive test

Related Article:

Emerging Roles of Antiangiogenic and Angiogenic Proteins in Pathogenesis and Prediction of Preeclampsia

Marshall D. Lindheimer and Roberto Romero
Hypertension 2007 50: 35-36. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				A. B. Singhal, W. T. Kimberly, P. W. Schaefer, and E. T. Hedley-Whyte Case 8-2009 -- A 36-Year-Old Woman with Headache, Hypertension, and Seizure 2 Weeks Post Partum N. Engl. J. Med., March 12, 2009; 360(11): 1126 - 1137. [Full Text] [PDF]

				J. S. Gilbert, S. A.B. Gilbert, M. Arany, and J. P. Granger Hypertension Produced by Placental Ischemia in Pregnant Rats Is Associated With Increased Soluble Endoglin Expression Hypertension, February 1, 2009; 53(2): 399 - 403. [Abstract] [Full Text] [PDF]

				S. E. Maynard and R. Thadhani Pregnancy and the Kidney J. Am. Soc. Nephrol., January 1, 2009; 20(1): 14 - 22. [Abstract] [Full Text] [PDF]

				V. C. Sandrim, A. C.T. Palei, I. F. Metzger, V. A. Gomes, R. C. Cavalli, and J. E. Tanus-Santos Nitric Oxide Formation Is Inversely Related to Serum Levels of Antiangiogenic Factors Soluble Fms-Like Tyrosine Kinase-1 and Soluble Endogline in Preeclampsia Hypertension, August 1, 2008; 52(2): 402 - 407. [Abstract] [Full Text] [PDF]

				B. D. LaMarca, J. Gilbert, and J. P. Granger Recent Progress Toward the Understanding of the Pathophysiology of Hypertension During Preeclampsia Hypertension, April 1, 2008; 51(4): 982 - 988. [Full Text] [PDF]

				J. S. Gilbert, M. J. Ryan, B. B. LaMarca, M. Sedeek, S. R. Murphy, and J. P. Granger Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H541 - H550. [Abstract] [Full Text] [PDF]

				J. S. Gilbert, S. A. Babcock, and J. P. Granger Hypertension Produced by Reduced Uterine Perfusion in Pregnant Rats Is Associated With Increased Soluble Fms-Like Tyrosine Kinase-1 Expression Hypertension, December 1, 2007; 50(6): 1142 - 1147. [Abstract] [Full Text] [PDF]

				M. D. Lindheimer and R. Romero Emerging Roles of Antiangiogenic and Angiogenic Proteins in Pathogenesis and Prediction of Preeclampsia Hypertension, July 1, 2007; 50(1): 35 - 36. [Full Text] [PDF]